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Abstract
Objective: To determine the levels of the tumor markers carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1) and 
carbohydrate antigen 15-3 (CA 15-3) in the blood and pleural fluid of patients with benign or malignant pleural effusion, evaluating the 
sensitivity of each marker in these fluids. Methods: We prospectively evaluated 85 patients with pleural effusion. The study of the pleural 
fluid observed the criteria established in the literature. Levels of the markers were determined using electrochemiluminescence. The sensitivity 
was determined on the condition that the specificity was ≥ 90%. Results: Of the 85 cases, 36 (42.4%) were malignant, 30 (35.3%) were 
benign, and the results were inconclusive in 19 (22.3%). In the malignant cases, the CEA and CYFRA21-1 levels were higher in the pleural 
fluid than in the blood, which was not observed for CA 15-3. In the benign cases, the CYFRA21-1 levels were higher in the pleural fluid than 
in the blood, whereas the opposite was found for CEA and CA 15-3. There were significant differences between malignant and benign cases 
for all markers, in pleural fluid and blood. In the pleural fluid, the sensitivity of CEA, CYFRA21-1 and CA 15-3 was 69.4, 69.4 and 66.7%, 
respectively, and the combined sensitivity was 80.6%. In the blood, the sensitivity was 57.1, 71.4 and 48.6% for CEA, CYFRA21-1 and 
CA 15-3, respectively, and the combined sensitivity was 77%. Conclusion: The results suggest that these markers might be useful in the 
differentiation between malignant and benign pleural effusion.
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Introduction
The etiological diagnosis of pleural effusion is 
frequently a problem in clinical practice, especially 
in terms of the differentiation between malignant 
and benign pleural effusion, due to the significant 
difference in the treatment and prognosis involved.(1) 
Statistics for the United States show that the annual 
number of new cases of pleural effusion is over 
1,000,000, approximately 200,000 of which are 
found to be associated with a malignant disease.(2,3) 
The majority of neoplasms can cause pleural effusion 
during their progression. The malignant disease most 
often associated with pleural effusion is lung cancer, 
which accounts for up to 30% of all cases of malig-
nant pleural effusion.(4) Lung cancer is followed by, in 
order of frequency, breast cancer and the lymphomas, 
which, when accompanied by lung cancer, account for 
68% of all cases of malignant pleural effusion.(3) The 
cytopathologic study of the pleural fluid is the diag-
nostic method most often used in the identification 
of malignant pleural effusion and has a sensitivity of 
approximately 50%, which can be increased by up to 
30% if needle biopsy of the pleura is performed.(1,5) 
Due to the low sensitivity of the method, the results 
can be inconclusive in terms of the identification of 
malignancy, and invasive procedures such as thora-
coscopy might be necessary.(2,3)
In the attempt to improve the identification of 
malignant cases, various studies have reported the 
usefulness of biological tumor markers.(6-9) These tumor 
markers are macromolecules produced by neoplastic 
cells or whose production is increased in the presence of 
neoplasia.(10) These markers can be detected in various 
biological specimens such as blood, serous liquid, 
and tissue samples.(8) The markers present different 
sensitivity and specificity according to the histological 
type of the primary tumor. Therefore, cytokeratin 19 
fragment (CYFRA21-1) presents good sensitivity for 
non-small cell bronchogenic carcinomas, especially 
those of the squamous type(5,11); levels of carbohydrate 
antigen 15-3 (CA 15-3) are often elevated in patients 
with advanced breast cancer(11); and levels of carci-
noembryonic antigen (CEA) are elevated in various 
malignant diseases, especially those of epithelial 
origin.(8) Studies have demonstrated that combining 
tumor markers improves their sensitivity in the diag-
nosis of malignant effusion.
Although there are a number of studies in the 
international literature involving the analysis of 
biological tumor markers in pleural fluid as a means 
of identifying associations with thoracic neoplasms, 
only a few such studies have been conducted in 
Brazil,(6,12) and we found no studies in which biolog-
ical tumor markers were analyzed in more than one 
type of biological material simultaneously. 
Therefore, our objective was to evaluate the 
determination of the tumor markers CEA, CYFRA21-1 
and CA 15-3 in blood and pleural fluid of patients 
with pleural effusion without previous diagnostic 
investigation, as well as to assess their usefulness as 




The population was composed of 85 consecu-
tive patients referred to the pulmonology sector of 
a university hospital, over an eight-month period, 
for the investigation of pleural effusion. All patients 
agreed to participate in the study and gave written 
informed consent. Three patients refused to allow 
the collection of blood samples but agreed to allow 
the collection of biological material through pleural 
puncture. None of the patients had previously 
been investigated in terms of the pleural effusion, 
nor were any of them being treated for malignant 
disease (with chemotherapy or radiotherapy) or 
for tuberculosis (with anti-tuberculosis drugs). An 
established questionnaire was used to collect data 
regarding demographics (age, gender, and profes-
sion), smoking (past and present),(13) the aspect of 
the pleural fluid, respiratory symptoms, information 
on past/present diseases, complimentary exams, and 
recent/present use of medication. In the differen-
tiation between exudates and transudates, we used 
the criteria established by Light.(14) The effusion 
was considered malignant when the cytopathologic 
study of the pleural fluid or the anatomopathological 
study of the pleural samples indicated malignancy. 
The pleural effusion was considered benign when 
the cytopathologic study of the pleural fluid or the 
anatomopathological study of the pleural samples 
was negative for malignancy, as well as when the 
accumulation of pleural fluid was accompanied by 
one the following conditions:
a) Parapneumonic effusion or empyema, 
according to Light(15);
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b) Tuberculosis: patients in whom the biopsy 
findings were suggestive of active tuberculosis 
with caseating granuloma and the cytology 
of the pleural fluid revealed a predominance 
of lymphocytes or an adenosine deaminase 
level > 40 IU;
c) Congestive heart failure: the study of the fluid 
revealed transudate or exudate, in patients 
with decompensated heart failure; and
d) Liver disease: transudative pleural effusion in 
patients with liver disease, with no other iden-
tifiable cause of the pleural effusion.
The evaluation of the pleural effusion was 
considered inconclusive when the cytopathologic 
study of the pleural fluid and the morphologic 
examination of the pleura did not indicate the 
cause of the pleural effusion. These cases were not 
included in the determination of the markers.
Collection of biological material 
Blood samples were simultaneously collected 
to determine the levels of tumor markers and 
the biochemical levels of lactate dehydrogenase, 
albumin, and total proteins. Percutaneous thoracic 
puncture was used to collect the pleural fluid, 
which was sent for biochemical testing, leukocyte 
measurement, culture, and smear cytology. Pleural 
biopsy was performed in the exudates for an anato-
mopathological study. Serum and pleural fluid were 
stored in aliquots of 10 mL at –80 °C for later deter-
mination of the tumor marker levels.
Determination of tumor marker levels
The electrochemiluminescence method was used 
to determine the levels of CYFRA21-1, CA 15-3, and 
CEA. This was achieved with an immunoassay analyzer 
(Elecsys® 2010; Roche, Mannheim, Germany) and 
commercial kits for each marker. When the level of 
a given marker surpassed the detection limit of the 
method, a dilution of 1:100 was used. The values 
established for the respective markers in the serum 
(according to the manufacturer) were as follows: 
CEA = up to 5 ng/mL; CYFRA21-1 = up to 3 ng/mL; 
and CA 15-3 = up to 40 ng/mL.
Statistic methodology
In the data analysis, associations between 
categorical variables were evaluated using the 
Fisher-Freeman-Halton exact test.(16) The compar-
ison among the values for each marker, in serum 
and in pleural fluid, was carried out using the 
(nonparametric) sign test. The comparison between 
the values for two markers, in serum and in pleural 
fluid, was carried out using the Mann-Whitney 
test. To establish the sensitivity of the markers, 
a cut-off point was determined for each, using a 
receiver operating characteristic (ROC) curve, under 
the condition of specificity equal to or greater 
than 90%. In the construction of the ROC curves, 
the patients with malignant effusion were consid-
ered cases, and the patients with benign effusion 
were considered controls. The effectiveness of the 
combination of the three markers to distinguish 
between malignant and benign effusion was evalu-
ated by constructing multivariate logistic regression 
models.(17) In the construction of these models, the 
three markers were considered independent varia-
bles. The response variable was composed of the two 
categories of pleural effusion (malignant or benign), 
and malignant effusion was the category of interest 
from the prediction point of view. In all tests, the 
level of significance that would allow the rejection 
of the null hypothesis was set at p < 0.05.
Ethical aspects
The study design was approved by the Oswaldo 
Cruz University Hospital Committee for Ethics and 
Research (protocol nº. 196/96).
Results
Of the 85 patients studied, 36 (42.4%) were 
diagnosed with malignant pleural effusion, and 
30 (35.3%) were diagnosed with benign effusion. 
The results were inconclusive in 19 (22.3%).
Table 1 shows the distribution of the patients 
by age and gender. The etiologic diagnoses of the 
cases of pleural effusion can be seen in Table 2.
The inconclusive cases were not evaluated. 
Approximately 27% of the malignant cases were 
associated with lung tumors and 13.8% with breast 
tumors. In the benign cases, tuberculosis prevailed. 
The cytology of the pleural fluid provided the diag-
nosis in 25 (69.4%) of the cases of malignant pleural 
effusion.
Table 3 shows the medians, together with the 
first and third quartiles, for the pleural fluid/serum 
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tumor marker levels in the malignant and benign 
cases.
In the patients with malignant pleural effusion, 
the CYFRA21-1 and CEA levels were significantly 
higher in the pleural fluid than in the serum (sign 
test: p < 0.001 and p = 0.014, respectively). However, 
there was no statistically significant difference 
between the serum and pleural fluid in terms of the 
levels of CA 15-3 (sign test: p = 1.00).
In the cases of benign pleural effusion, CYFRA21-
1 levels were significantly higher in the pleural fluid 
than in the serum (sign test: p < 0.001). However, 
the levels of CEA and of CA 15-3 were significantly 
lower in the pleural fluid.
There were statistically significant differences 
between the malignant and benign cases in terms 
of the pleural fluid/serum levels of CYFRA21-1, 
CEA, and CA 15-3 (Mann-Whitney test: p < 0.001), 
the only exception being serum levels of CA 15-3 
(p = 0.045).
The sensitivity and specificity of each marker are 
represented in Table 4. The cut-off points for each 
marker were chosen based on their respective ROC 
curves, under the condition of specificity equal to 
or greater than 90%. Under that condition, it was 
determined that, in the pleural fluid, the greatest 
sensitivity was achieved with the combination of 
CYFRA21-1 and CEA (69.4% for both). When all 
three markers were used in conjunction, the sensi-
tivity increased to 80.6%.
In the blood, CYFRA21-1 presented the greatest 
sensitivity (71.4%). When the three markers were 
combined, the sensitivity rose to 77%.
There were no statistically significant differences 
among the smokers, former smokers and nonsmokers 
in terms of the levels of any of the markers, in serum 
or in pleural fluid (Kruskal-Wallis test; p > 0.462 for 
all comparisons).
Discussion
Recognizing patients with pleural malig-
nancy if fundamental, since, unlike those with 
the benign form, for whom the prognosis is favo-
rable, such patients have a mean survival of three 
to six months.(18) Thoracentesis with cytopathologic 
study of the pleural fluid, the principal diagnostic 
method, presents great variation in its sensitivity 
(40-60%),(1,2,18) which is increased by up to 7% 
when a pleural biopsy is also performed.(14) Although 
surgical procedures (thoracoscopy and thoracotomy) 
present better diagnostic sensitivity for malignant 
cases (90%), they are expensive and are not avail-
able at all medical centers.(20)
Of the 85 patients evaluated in the present 
study, 92.9% presented pleural exudate. There was 
a discrete predominance of malignant pleural effu-
sion (42.4%) over benign pleural effusion (35.3%). 
These results are similar to those found in the litera-
ture, reflecting the frequency of neoplastic pleural 
effusion, which can account for as much as 50% 
of the pleural exudates.(21) The distribution found 
might be related to the fact that this study was 
carried out at a facility that is a regional referral 
Table 2 - Distribution of the cases of malignant and 










































Data presented as mean and standard deviation.
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center for the diagnosis and treatment of thoracic 
tumors, which might have affected the selection of 
cases. Twenty-two (76%) of the benign cases were 
secondary to tuberculosis. This reflects the high 
prevalence of tuberculosis in Brazil, and the most 
common presentation of extrapulmonary tubercu-
losis is the pleural form.(22,23) This high prevalence 
among the benign pleural exudates was also found 
in other studies.(20,24,25) In 19 cases (22.3%), it was 
not possible to differentiate between the benign 
and malignant cases. Similar results have been 
described by other authors who reported that, even 
after cytopathologic study of the pleural fluid and 
pleural biopsy, approximately 20% of the cases of 
pleural effusion remain undiagnosed.(26)
The difficulty in making the differential diagnosis 
between benign and malignant pleural effusion 
represents a great problem in the study of the condi-
tion. Among the potential factors responsible for 
this difficulty are the inappropriate collection and 
laboratory manipulation of the pleural fluid, as well 
as an insufficient quantity of pleural material.(5)
In this context, determination of tumor marker 
levels represents an auxiliary method of identifying 
malignant pleural effusion. The potential of using 
such markers to differentiate between malignant 
and benign effusions has been mentioned in various 
studies.(5-9,20,21,27,28) However, it is difficult to draw 
comparisons among such studies, since there are 
differences in the number/type of markers evalu-
ated, as well as a significant lack of uniformity in 
the laboratory methodology and the parameters 
established as cut-off points to determine specifi-
city/sensitivity, together with the detection of 
markers in benign diseases and the prevalence of the 
tumor type in the groups studied. Although some 
studies have employed a single tumor marker, the 
combination of more than one marker raises their 
sensitivity in detecting malignant neoplasms.(5,7,28,29) 
In the present study, the markers CEA, CYFRA21-1, 
and CA 15-3 were chosen based on the observation 
that the majority of the studies have at least two of 
these in their marker panel, suggesting that their 
inclusion would increase the diagnostic sensitivity 
and specificity in the detection of malignant pleural 
effusion.(7,20,21,29)
In this study, the concomitant determination of 
serum and pleural levels of the CEA, CYFRA21-1 
Table 3 - Median, first and third quartiles of the markers CYFRA21.1, CEA and CA15-3, obtained in the serum and 
pleural fluid of the patients with malignant or benign pleural effusion.
Marker Pleural effusion
Malignant Benign
Pleural fluid (n = 36) Serum (n = 35) Pleural fluid (n = 30) Serum (n = 28)
Median Q1-Q3 Median Q1-Q3 Median Q1-Q3 Median Q1-Q3
CYFRA21.1 101.1 25.2-478.3 6.4 2.4-17.3 12.2 6.9-23.2 1.0 0.7-1.9
CEA 27.6 0.8-496.8 4.6 1.0-17.7 0.4 0.2-1.2 0.9 0.3-1.7
CA 15-3 43.9 19.4-167.4 28.6 13.6-81.3 15.9 9.0-20.7 19.8 15.5-23.2
Q1: first quartile; Q3: third quartile.
Table 4 - Cut-off point, sensitivity and specificity of the markers CEA, CYFRA21-1 and CA 15-3.
Biological material/marker Cut-off point Sensitivity (%) Specificity (%)
Pleural fluid
CYFRA21-1 34.99 69.4 90.0
CEA 1.86 69.4 90.0
CA 15-3 22.38 66.7 90.0
CYFRA21-1 + CEA + CA 15-3 0.333* 80.6 90.0
Serum
CYFRA21-1 3.12 71.4 93.0
CEA 3.35 57.1 93.0
CA 15-3 30.86 48.6 93.0
CYFRA21-1 + CEA + CA 15-3 0.554* 77.0 93.0
*probability estimated in the logistic regression model.
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and CA 15-3 markers had the objective of deter-
mining whether the concentrations of these markers 
were comparable in the two sample types, since 
the pleural fluid is a blood filtrate and, as such, 
should be correlated with the blood. However, some 
authors have reported that the concentrations of 
tumor markers are greater in the pleural fluid than 
in the serum, suggesting the local production of 
some markers, especially those such as CYFRA21-1 
(secreted by mesothelial cells), which might alter the 
overall sensitivity of the marker.(5,11,21)
In the present study, the sensitivity of each tumor 
marker was established through the construction of 
ROC curves, opting for specificity equal to or greater 
than 90%, with the purpose of decreasing the possi-
bility of obtaining false-positive results. Although 
the ideal specificity is 100% (no false-positives), such 
an index requires quite high cut-off points, signifi-
cantly reducing the sensitivity of the markers.(5)
The sensitivity of the three markers in the 
pleural fluid were similar (CYFRA21-1 = 69.4%, 
CEA = 69.4%, and CA 15-3 = 66.7%, for a specifi-
city of 90%). When the three markers were used 
in conjunction in the pleural fluid samples, the 
sensitivity increased to 80.6%. This finding is in 
agreement with those of other studies.(5,28-30)
There were differences among the markers 
in terms of their sensitivity in serum samples 
(71.4, 57.1, and 48.6% for CYFRA21-1, CEA, and 
CA 15-3, respectively), with a specificity of 93%. 
When the three markers were combined, the sensi-
tivity increased, especially for CEA and CA 15-3, 
justifying the use of this combination (overall 
sensitivity, 77%).
The levels of CYFRA21-1 and CEA were higher 
in pleural fluid than in serum (p < 0.001 and 
p = 0.0014, respectively). Similar results have been 
reported in other studies.(5,30) There was no statisti-
cally significant difference between the serum and 
pleural fluid levels of CA 15-3.
For all of the markers studied, there were statis-
tically significant differences between the serum 
and pleural fluid samples, as well as between the 
malignant and benign forms of pleural effusion. 
These results are similar to what has been found 
in other studies.(5,7,28) In the present study, the use 
of the tumor marker combination presented signifi-
cantly greater sensitivity for the identification of 
malignancy than did the cytopathological study 
(80.6 vs. 69.4%). A similar result was found by 
some authors.(21) It was not possible to determine 
the sensitivity of the markers according to the histo-
logical type of the neoplasms, since the minimal 
number of cases did not allow such evaluation.
In the present study, no statistically significant 
differences were found among the smokers, former 
smokers and nonsmokers in terms of the tumor 
marker levels, whether in serum or in pleural fluid. 
Similar results were reported by other authors who 
evaluated serum levels of CYFRA21-1.(31) However, 
some studies have demonstrated that concentrations 
of CEA are higher in smokers than in nonsmokers, 
and that high CEA concentrations are associated 
with the subsequent development of neoplasms.(32)
The ideal marker would be sensitive and specific, 
as well as reflecting the tumor burden, being 
predictive of tumor recurrence, and allowing the 
treatment response to be evaluated.(10) Although the 
biological markers currently available do not present 
this profile, they have the advantage of being rela-
tively affordable and are available in the larger cities. 
The determination of tumor marker levels is not 
routinely indicated. However, in cases of suspected 
malignancy and inconclusive initial findings, tumor 
marker levels should be determined prior to the 
performance of invasive procedures, thereby opti-
mizing the cost-benefit ratio.
The present study represents an advance in the 
investigation of pleural effusion at our facility.
Our findings demonstrate that determining 
serum and pleural fluid levels of the tumor markers 
CYFRA21-1, CEA, and CA15-3 is useful in differ-
entiating between benign and malignant pleural 
effusion.
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